Abbott Laboratories AI Adoption Tracker
Last updated: August 9, 2026
Overview
Abbott Laboratories has positioned itself as a leader in AI integration across healthcare, with significant developments throughout 2025-2026 [1]. The company launched Libre Assist, an AI-powered feature within its Libre app that uses generative AI to predict how foods affect glucose levels before consumption [2]. Abbott elevated AI-savvy CIO Sabina Ewing to the executive suite and established a Data Use & Ethics Board with formal AI governance principles [3]. The company published a comprehensive five-point Responsible AI framework emphasizing safety, transparency, fairness, and impact [4]. Beyond diabetes care, Abbott deployed AI in cardiovascular imaging through its Ultreon platform and partnered with iCardio.ai for electrophysiology applications [5][6].
- [1] Abbott's AI Strategy: Analysis of AI Dominance in Medical Devices
- [2] Abbott's new Libre Assist app feature tackles a top need for people living with diabetes
- [3] Abbott Laboratories - IMD business school for management
- [4] Abbott and responsible AI
- [5] Artificial Intelligence at Abbott - Two Current Use-Cases
- [6] Abbott, iCardio.ai partner on AI for electrophysiology imaging
AI Maturity Index
Radar Comparison
Peer Comparison: Abbott Laboratories vs healthcare
Based on 66 companies in sector
| Dimension | Abbott Laboratories | Sector Avg | Diff |
|---|---|---|---|
| Adoption | 4.0 | 3.7 | +0.3 |
| Proficiency | 4.0 | 3.5 | +0.5 |
| Impact | 3.0 | 3.6 | -0.6 |
| Overall | 3.6 | 3.6 | 0.0 |
Key Metrics
AI Initiatives
Libre Assist
January 2026
AI-powered meal guidance feature within the Libre app that predicts glucose impact before eating
Uses generative AI to analyze food photos or text descriptions, provides color-coded glucose impact predictions (green/yellow/orange), offers personalized meal tips, and validates predictions using FreeStyle Libre CGM data
LARALAB Acquisition
October 2025
Acquisition of cardiac imaging AI technology company
Acquired LARALAB to expand heart.ai technology for structural heart intervention planning
AI Governance Framework
2025
Five-point Responsible AI framework establishing company principles
Framework emphasizes responsible use, safety, transparency, fairness, and impact. Includes Data Use & Ethics Board for enterprise AI oversight
iCardio.ai Partnership
September 2024
Collaboration on AI algorithms for electrophysiology imaging
Partnership to develop AI applications for EnSite X cardiac mapping system using 2D intracardiac echo images
Ultreon AI Imaging Platform
2024
AI-enabled optical coherence tomography (OCT) software for cardiovascular procedures
Provides real-time AI-generated calcium detection and blood vessel diameter measurements during heart stent procedures, trained on multi-vendor, multi-scanner patient data
Frequently Asked Questions
Libre Assist is an AI-powered feature in the Libre app that predicts how foods will affect glucose levels before eating, provides personalized meal guidance, and validates predictions using CGM data.
Abbott has established a five-point Responsible AI framework emphasizing safety, transparency, fairness, and impact, along with a Data Use & Ethics Board for governance.
Abbott uses AI in its Ultreon OCT platform for real-time cardiac imaging analysis and through partnerships for electrophysiology imaging applications.
In Application
| Application | Vendor | Use Case |
|---|---|---|
| Generative AI models | Not specified | Food impact prediction in Libre Assist feature |
| Machine learning algorithms | Internal development | Heart attack risk prediction and OCT imaging analysis |
Sources
Abbott's AI Strategy: Analysis of AI Dominance in Medical Devices
Abbott's new Libre Assist app feature tackles a top need for people living with diabetes
Abbott Laboratories - IMD business school for management
Abbott and responsible AI
Artificial Intelligence at Abbott - Two Current Use-Cases
Abbott, iCardio.ai partner on AI for electrophysiology imaging
Related Companies
About AI Tracker
AI Tracker is a research project by Larridin, the AI execution intelligence platform.
Methodology: We analyze earnings calls, press releases, partnership announcements, and product documentation. All assessments are based solely on publicly available information—no private customer data is used.
Maturity Scoring: Each dimension is rated on a 4-tier scale (Nascent → Emerging → Scaling → Leading) based on evidence from public sources. Industry averages are computed as the median across all tracked companies in the sector.